SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

85.1 1.49

Résumé

Variation du prix de l'action

24h

Actuel

Min

84.9

Max

85.25

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

35.869

63.808

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+1.94% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

353M

4.3B

Ouverture précédente

83.61

Clôture précédente

85.1

Sentiment de l'Actualité

By Acuity

50%

50%

150 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 avr. 2026, 23:48 UTC

Principaux Événements d'Actualité

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19 avr. 2026, 23:36 UTC

Principaux Événements d'Actualité

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19 avr. 2026, 22:47 UTC

Principaux Événements d'Actualité

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19 avr. 2026, 21:14 UTC

Principaux Événements d'Actualité

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19 avr. 2026, 21:14 UTC

Principaux Événements d'Actualité

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19 avr. 2026, 23:49 UTC

Market Talk
Principaux Événements d'Actualité

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19 avr. 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19 avr. 2026, 23:38 UTC

Principaux Événements d'Actualité

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19 avr. 2026, 23:36 UTC

Market Talk
Principaux Événements d'Actualité

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19 avr. 2026, 23:12 UTC

Principaux Événements d'Actualité

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19 avr. 2026, 23:10 UTC

Principaux Événements d'Actualité

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19 avr. 2026, 23:09 UTC

Principaux Événements d'Actualité

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19 avr. 2026, 23:08 UTC

Principaux Événements d'Actualité

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19 avr. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19 avr. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19 avr. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19 avr. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19 avr. 2026, 20:03 UTC

Principaux Événements d'Actualité

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19 avr. 2026, 20:03 UTC

Principaux Événements d'Actualité

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19 avr. 2026, 20:03 UTC

Principaux Événements d'Actualité

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19 avr. 2026, 20:03 UTC

Principaux Événements d'Actualité

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18 avr. 2026, 01:00 UTC

Principaux Événements d'Actualité

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 avr. 2026, 22:58 UTC

Résultats

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 avr. 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 avr. 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 avr. 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 avr. 2026, 20:52 UTC

Résultats

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 avr. 2026, 20:50 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

17 avr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 avr. 2026, 20:29 UTC

Résultats

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

1.94% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  1.94%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

150 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat